Here's why IKT needs immediate attention.


Nasdaq Breakout Idea (IKT) Jumps The Opening Bell To Shoot To New 1-Month High (200-Day SMA Breakdown?)

March 14th

Greetings Readers,

Here's why IKT needs immediate attention.

Coming out hot this morning, IKT just set a new 1-month high when it reached $.82.

But this is more important. Right now, IKT has moved above its 200-Day Simple Moving Average (SMA) in what could become a potential squeeze scenario.

As I noted in my previous messages, IKT closed Monday above its 50-Day SMA and its 13-Day Exponential Moving Average (EMA).

If potential resistance at the 200-Day SMA level breaks down for IKT, it could draw serious attention to this Nasdaq profile as it will be trading firmly above 3 of the most important lines of potential support.

Plus, don't forget IKT's low float of approximately 18.48Mn shares and the huge FDA ruling it's coming off of last week.

Long story short? We could be staring at a potential powder keg in IKT. Don't waste another second pulling up this Nasdaq Biopharma.


Did you see what my (3/7/23) Nasdaq profile did?

If not, it's okay. To make up for it, I've got a new breakout idea for Tuesday's opening bell. But more on that in a sec...

My 3/7 alert put together an impressive 3-day surge from an open of $1.61 to a high of $2.07 on (3/9/23).

That's a short term blast of approximately 28%.

Solid stuff. But it's time to turn up the heat.

I've got right here a complete report on a Nasdaq Biopharma company that just had a game-changing FDA ruling announcement just last week.

If it's as important as I think it is, it may just be a matter of time until it starts garnering Wall Street's attention.

Also this:


As of 2:30PM EST Monday, this profile was trading above 2 key lines of potential support in its 50-Day Simple Moving Average (SMA) and its 13-Day Exponential Moving Average.

If a breakdown of potential resistance occurs at its 200-Day SMA, it could create a possible squeeze scenario.

And if you take a look at the chart above, or any chart of this Biopharma breakout idea, you'll see that it has traded over $1.00 per share in the previous 50-Day stretch.

Now, do we expect a push to that January high this week? No, but the potential needs to be noted for this profile that made a clean double (2X) in under a month from the end of December to the end of January.

Between the positive FDA ruling news, a potential squeeze situation, a low float, several important collaborations with leading research institutions, and an addressable market that could swell significantly over the next decade, now may be the perfect time to research this company.

For Tuesday, March 14th's opening bell, here's a Nasdaq Biopharma to watch closely:

*Inhibikase Therapeutics, Inc. (IKT)*

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders.

Today, IKT has several potential breakout catalysts to know this second. Here they are:

No. 1 - FDA Ruling Paves Way For IKT To Move Forward With Key Clinical Trial

No. 2 - A Low Float Could Set The Stage For Major Volatility

No. 3 - The Potential Market For Treating Parkinson's Disease Is Immense (Projected Global Value Of Over $12Bn Within A Decade

No. 4 - Company Has Strong Partnerships With Leading Research Institutions

But more on those in a second...

Novel Product Candidates for the Treatment of Neurological Diseases

Inhibikase Therapeutics pursues the discovery and characterization of the biochemistry of disease inside and outside of the brain. With a deep commitment to scientific discovery and translation, we pursue any path necessary to target key biochemical checkpoints to disrupt the disease process. Our current focus is the analysis and disruption of neurodegenerative pathways in the brain and gastrointestinal tract that lead to Parkinson’s and related diseases.

Key technologies include:

RAMP™: Re-engineering Approach with Metabolism Preserved, a method of designing novel medications by learning from clinically evaluated and/or marketed drug products to build in desirable, clinically validated safety or pharmacology characteristics from the template into new drug substances.

Prodrug delivery methods: Novel prodrug linkers that enhance drug absorption, delivery and/or suppress undesired on-dosing side effects.

Multi-Therapeutic Pipeline Of Kinase Inhibitor Therapeutics

Focused on developing novel therapeutics across a wide therapeutic spectrum including neurodegeneration, oncology and infectious diseases.

  • Aim to discover novel therapeutics by modeling human disease using the Company’s Re-engineering Approach with Metabolism Preserved (RAMP) medicinal chemistry platform
  • IkT-148009: Lead Abelson Tyrosine Kinase (c-Abl) inhibitor program has the potential to be a disease-modifying treatment for Parkinson’s disease (PD) and related disorders. Phase 2a ‘201’ trial in Parkinson’s to begin screening patients in 1Q23.
  • IkT-001Pro: First oncology product is a BCR-Abl inhibitor with a potentially-improved safety profile to standard of care imatinib mesylate for leukemias and gastrointestinal cancers. Bioequivalence trial compared to 400 mg imatinib mesylate completed 1 cohort 4Q22 in first part of two-part study. Anticipated completion of bioequivalence in 1H23.
  • Robust patent portfolio with protection to 2033 (oncology) and 2036 (neurodegeneration).
  • $20.8Mn in grants and contracts from NIH, DoD, the Michael J. Fox Foundation and the Georgia Research Alliance, all peer-reviewed; $63Mn gross proceeds in in-vest-or capital in 2021, $10Mn in 2023
  • Highly-experienced management team, consultants, Board of Directors and Scientific Advisory Board


Multi-Indication Pipeline in Neurodegeneration, Oncology and Infectious Disease



Upcoming Milestones: 1Q 2023

  • Open up to 29 of 201 trial sites 1Q23
  • Restart and screen patients for 201 trial at two doses
  • Complete 200 mg, 7-day dosing PK profile in older and elderly healthy subjects and request addition of 200 mg dose to 201 trial
  • Implement PK bridging, food-effect studies
  • Add 12-month open-label safety extension study into 201 trial with FDA agreement
  • Characterize novel compounds as follow-ons to IkT-148009
  • Complete up to 3 cohorts in Part 1 of 501 trial
  • Explore commercial manufacturing scale-up
  • Develop superiority study for IkT-001Pro relative to standard-of-care in CML

Grab sources here: Company Website - Company Presentation


And as I mentioned above, IKT has multiple potential catalysts to soak in right now. Check them out:

No. 1 IKT Potential Catalyst - FDA Ruling Paves Way For IKT To Move Forward With Key Clinical Trial

Inhibikase Therapeutics Announces FDA has Lifted the Full Clinical Hold on IkT-148009 in Multiple System Atrophy

- Advancing model studies of IkT-148009 in MSA; early data has shown a substantial neuroprotective benefit in response to c-Abl inhibition by IkT-148009 –

- MSA IND Opened, the 5th in the Company's history –

- Advancing model studies of IkT-148009 in MSA; early data has shown a substantial neuroprotective benefit in response to c-Abl inhibition by IkT-148009 –

- MSA IND Opened, the 5th in the Company's history –

- Planned Phase 2a '202' clinical trial will evaluate therapeutic benefit of IkT-148009 over 6 months –

BOSTON and ATLANTA, March 8, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced the U.S. Food and Drug Administration ("FDA" or "Agency") has lifted the full Clinical Hold on IkT-148009, the Company's c-Abl inhibitor, in Multiple System Atrophy (MSA) allowing the Company to proceed with its plans for a future Phase 2 clinical trial in MSA.

"We are grateful for the expeditious review by the FDA of our response to the Clinical Hold on IkT-148009 in MSA," stated Milton H. Werner, Ph.D., President and Chief Executive Officer of Inhibikase Therapeutics. "As with our work in Parkinson's, preclinical models have highlighted the therapeutic potential of IkT-148009 in MSA. One of two ongoing model studies has shown a substantial neuroprotective benefit in response to c-Abl inhibition by IkT-148009. With the clinical hold lifted and the IND now open, we look forward to completing these studies prior to initiation of the Phase 2a trial in this patient population."

The planned '202' trial will evaluate the safety, tolerability and pharmacokinetics of IkT-148009 in MSA patients over 6 months of once daily dosing at one of two oral doses. Secondary and exploratory endpoints will evaluate clinical benefit using a modification of the Total Unified MSA Rating Scale (UMSARS), assessment of quality of life. severity of symptoms arising from orthostatic hypotension, and the levels of neurofilament light chain in peripheral blood and spinal fluid. Additionally, biomarkers of treatment benefit will be explored by measuring levels of phosphorylated alpha-synuclein in spinal fluid, peripheral blood and skin. Clinical effect on the progression of atrophy will be monitored in the trial using MRI.


Read the full article here.


No. 2 IKT Potential Catalyst - A Low Float Could Set The Stage For Major Volatility

According to the Yahoo Finance website, IKT has a low float.

The website reports this profile to have approximately 18.48Mn shares in its float.

Why is that important? It's important on one crucial level. Volatility.

Could positive 2023 company news help provide a near term spark?


No. 3 IKT Potential Catalyst - The Potential Market For Treating Parkinson's Disease Is Immense (Projected Global Value Of Over $12Bn Within A Decade) (1)

With a focus on neurodegenerative and infectious diseases, IKT has an opp. to secure a significant share of this market.

Market research indicates that the global neurodegenerative disorder therapeutics market could see a compound annual growth rate of 8.1%, growing from $15.86Bn in 2022 to $17.14Bn in 2023.

This growth is expected to continue at a CAGR of 8.4%, reaching $23.65Bn in 2027, driven by an aging population with a higher prevalence of neurodegenerative disorders.

By 2050, the number of people over 60 years old is estimated to increase to 2.1 billion, with those over 80 years tripling to 425 million.

The Alzheimer's Association predicts that the number of Americans with Alzheimer's disease will rise to approximately 14 million by 2050, further increasing the demand for neurodegenerative disorder therapeutics.

Therefore, a treatment from IKT could be a truly game-changing opp.


No. 4 IKT Potential Catalyst - Company Has Strong Partnerships With Leading Research Institutions

Collaborations are central components of IKT's strategy to build and advance their pipeline of product candidates.

Through the National Institutes of Health (NIH) research grants awarded to Dr. Werner, the company has subcontracted research projects in the biochemistry of neurodegeneration to Johns Hopkins University, Arizona State University, the University of Bordeaux and the Vienna (Austria) Medical University.

In oncology, IKT has subcontracted research work to the University of California, San Francisco and the CML Consortium and consulted with clinicians at the Memorial Sloan-Kettering Cancer Center and the Medical College of Wisconsin.

The company's research endeavors have been validated by private and public granting agencies, to include the Michael J. Fox Foundation, and the National Institute of Neurological Disease and Stroke, the National Cancer Institute and the National Institute of Allergy and Infectious Disease.

IKT believes that accessing external innovation is important to their success and they plan to remain active in accessing external innovation through business development activities and awarding of private, state and federal grants through institutions such as NIH and DoD.


IKT Recap - 4 Potential Catalysts That Could Provide This Nasdaq Biopharma With A Breakout Spark

No. 1 - FDA Ruling Paves Way For IKT To Move Forward With Key Clinical Trial

No. 2 - A Low Float Could Set The Stage For Major Volatility

No. 3 - The Potential Market For Treating Parkinson's Disease Is Immense (Projected Global Value Of Over $12Bn Within A Decade

No. 4 - Company Has Strong Partnerships With Leading Research Institutions


Coverage is officially initiated on IKT. Do this when you can:


Get IKT on your radar now.


Kai Parker


Source 1

(Always Remember The Stock Prices Could Be Significantly Lower Now From The Dates I Provided.)

StockWireNews (stockwirenews . com) is owned by SWN Media LLC, a limited liability company. Disclosure: I am not a lice.nsed finan.cial adviser. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. StockWireNews full disclosure is to be read and fully understood before using StockWireNews website, or joining StockWireNews' email or text list. By viewing StockWireNews website and/or reading StockWireNews email or text newsletter you are agreeing to StockWireNews full disclosure which can be read at An owner of SWN Media LLC owns and operates smallcapfirm . com (“SCF”), owns and operates fierceinvestor . com (“FI”), and owns and operates stockstreetwire . com ("SSW"). From time to time, StockWireNews, SCF, FI, and/or SSW will publicly disseminate information about a company via website, email, SMS and other points of media. Ownership of "FI" and "SSW" has now moved to a single individual. Pursuant to an agreement between SWN Media LLC and TD Media LLC, StockWireNews has been hired for a period beginning on 3/13/23 and ending on 3/14/23 to publicly disseminate information about (IKT) via Website, Email and SMS. SWN Media LLC was paid twenty-five thousand USD via bank wire transfer. We own zero shares of (IKT). A member of SWN Media LLC is also a member of TD Media LLC. Pursuant to an agreement between TD Media LLC and JRZ Capital LLC, TD Media LLC has been hired for a period beginning on 03/02/2023 and ending on 03/17/2023 to publicly disseminate information about (IKT:US) via digital communications. We have been paid one hundred seventy five thousand dollars USD. We own zero shares of (IKT:US).